B la n d -A lt m a n g r a p h f o r r e s u lt s b e t w e e n N o t D e t e c t e d -5 0 0 0 c / m L . ( n = 6 4 )
A v e r a g e H IV -1 T a q M a n v 2 a n d G e n e X p e r t A v e r a g e H IV -1 T a q M a n v 2 a n d G e n e X p e r t • undetectable (16, 8.8%)
• below the benchmark test lower limit of detection (<20 copies/mL) (10, 7.9%)
• low range (20 -5,000 copies/mL) (43, 33.1%)
• medium (5,000 -50,000 copies/mL) (24, 18.5%)
• high range (>50,000 copies/mL) (29, 22.3%)
Thirteen samples (10%) were invalid as a result of insufficient sample (<1 mL).
Samples in the lower analytical range of <1,000 copies/mL showed little variance when compared to Roche CAP/CTM using Bland Altman analysis.
Reproducibility was assessed in the high, medium and low range with-in 1-2 SD of the mean.
Sixteen replicates of a commercial external quality control sample, Acrometrix HIV-1 Low Control, showed very good reproducibility.
Method
To date, a total of 130 plasma samples have been tested over the analytical range and compared to a benchmark real-time PCR system -the Roche COBAS AmpliPrep/COBAS TaqMan system (CAP/CTM) Seventy four samples (56.9%) were of a known subtype comprising of subtype B (37.6%), AE (7.7%), C (4.6%), AG (1.5%) and mixed (4.6%).
Additional samples consisting of an external quality control samples run over multiple days, and samples with HIV-1 RNA not detected or below the lower limit of the assay were also tested to assess performance.
Conclusions
The HIV-1 Quant Assay performed on the GeneXpert® Instrument Systems correlated with a commonly used HIV RNA test in plasma and offered significant workflow advantages.
Time to result is approximately 90 minutes.
Sample required is 1 mL plasma.
The system has a small footprint and requires no further consumables other than the singleuse test cartridges.
Further studies are planned to fully assess the assay performance.
